CareDx Q1 revenue rises 39%, beats estimates

CareDx

28/04/2026 21:12

Overview

US transplant diagnostics firm's Q1 revenue rose 39%, beating analyst expectations

Company raised 2026 revenue and adjusted EBITDA guidance, announced $100 mln share buyback

Outlook

CareDx raises 2026 revenue guidance to $447 mln to $465 mln

Company raises 2026 adjusted EBITDA guidance to $43 mln to $57 mln

Result Drivers

TESTING SERVICES GROWTH - Higher testing volumes, increased average revenue per test, and improved collections drove 48% year-over-year growth in testing services revenue

PATIENT AND DIGITAL SOLUTIONS - Revenue rose 33% year-over-year, supported by adoption of new transplant centers and increased use of digital solutions

OPERATIONAL EXECUTION - Record cash collections and focus on high-margin testing services contributed to profitability

Company press release: ID:nBwb0J80sa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$118 mln
$104.03 mln (8 Analysts)
Q1 Non-GAAP net income per share
Beat
$0.34
$0.13 (6 Analysts)
Q1 EPS
$0.05
Q1 Non-GAAP net income
$18 mln
Q1 Net Income
$3 mln
Q1 Adjusted EBITDA
$19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CareDx Inc is $26.00, about 19% above its April 27 closing price of $21.85

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)